Skip to main content

Company profile

Capricor Therapeutics, Inc.

Pipeline4 assets

DeramiocelCAP-1002 / allogeneic CDCs / Neuromuscular disease
Duchenne muscular dystrophy (DMD)Phase 3in progressBecker muscular dystrophy (BMD)Preclinicalin progress
StealthX™STX-S / Exosome-based vaccine / Infectious disease
SARS-CoV-2Phase 1in progress
StealthX™Therapeutic Exosomes
EvaluatingPreclinicalin progress
CDC-ExosomesExosome Platform / Neuromuscular disease
Duchenne muscular dystrophyPreclinicalin progress

Latest news16 items

Oct 5, 2026

Capricor Therapeutics Presents Positive HOPE-3 Open-Label Extension Data on Upper Limb Function in Duchenne Muscular Dystrophy at 2026 World Muscle Society Congress

Presentation / Abstract • Phase 3WMS late-breaking poster presentation Mon, Oct 5, 2026, 9:00 AM EDT

Sep 17, 2026

Capricor Therapeutics to Present HOPE-3 and HOPE-3 Open-Label Extension Data at 2026 World Muscle Society Congress

Presentation / Abstract • Phase 3WMS late-breaking poster session Tue, Sep 29, 2026, 8:30 AM EDT

Aug 24, 2026

Capricor Therapeutics Announces Extension of PDUFA Target Action Date as FDA Continues Review of Deramiocel BLA

Aug 13, 2026

Capricor Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Aug 10, 2026

Capricor Therapeutics to Report Second Quarter 2026 Financial Results and Provide Recent Corporate Update on August 13

Jul 30, 2026

Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel

Jul 29, 2026

The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy

Trial Results • Phase 3Results event Wed, Jul 29, 2026, 10:05 AM EDT

Jul 27, 2026

Capricor Comments on Briefing Materials Ahead of July 29 FDA Advisory Committee Meeting for Deramiocel

Jun 26, 2026

Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

Jun 26, 2026

Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference

Presentation / Abstract • Phase 3Late-breaking presentation Sat, Jun 27, 2026

Jun 8, 2026

Capricor Therapeutics to Present at Upcoming Investor Conferences

May 28, 2026

Capricor Therapeutics Expands Commercial Leadership Team

May 12, 2026

Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 7, 2026

Capricor Therapeutics Takes Legal Action to Protect Patient Access to Deramiocel for Duchenne Muscular Dystrophy

May 4, 2026

Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12

Apr 22, 2026

Capricor Therapeutics Announces Late-Breaking Presentation of HOPE-3 Phase 3 Results at the American Academy of Neurology 2026 Annual Meeting

Trial Results • Phase 3

Capricor Therapeutics, Inc. • Endpoint Arena